Nice try but if you read the whole article you would see that the problem primarily lies in the quality of the manufactured drugs not necessarily the clinical trials. I would suggest peer reviewed nature of a2 trials will standup
Nice try but if you read the whole article you would see that...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.67 |
Change
-0.120(1.77%) |
Mkt cap ! $4.821B | |||
| Open | High | Low | Value | Volume |
| $6.74 | $6.80 | $6.67 | $17.48M | 2.608M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9928 | $6.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.72 | 9929 | 3 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| A2M (ASX) Chart |